查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1250773

到 2028 年的肝素市場預測——按來源、給藥途徑、劑型、成分、治療方法、產品、應用、分銷渠道、最終用戶和地區進行的全球分析

Heparin Market Forecasts to 2028 - Global Analysis By Source, Global Heparin Market, By Administration Route, Dosage Form, Ingredient, Therapeutics, Product, Application, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

據 Stratistics MRC 預計，2022 年全球肝素市場規模將達到 74 億美元，預計到 2028 年將達到 86 億美元，預測期內復合年增長率為 2.4%實現

肝素被認為是維持生命最重要的藥物之一。 肝素是一種抗凝劑。 肝素用於治療多種慢性疾病。 這種藥物具有很強的抗炎作用。 靜脈注射或皮下注射。 管理心臟、骨科、深靜脈血栓形成、肺栓塞和腎臟疾病。 它還用於管理主要的骨科手術，例如髖關節和膝關節置換術。 它可以防止患有某些疾病和接受心臟直視手術、旁路手術、腎透析和輸血等醫療程序的患者血液凝固。

根據 CDC 的數據，2022 年美國每年有 659,000 人死於心髒病，即每 4 人中就有 1 人死於心髒病，是美國的主要死因之一。它已經完成了。

市場動態：

驅動程序

慢性病和手術的患病率增加

接受骨科手術、深靜脈血栓形成、肺栓塞、腎臟疾病和心臟手術的患者數量增加，在這些手術中使用肝素導致肝素用量增加。 它的作用是減少血液凝固，防止手術過程中過度凝固，並且有一些標籤外用途。 肝素主要對某些患者有幫助，尤其是那些必須接受某些類型的手術或必須長時間臥床的患者。 這些因素正在推動市場需求。

約束

有害的副作用

誤用或不當使用肝素可能會導致關節疼痛、僵硬、腰痛、出血、吐血、傷口出血和腹痛。 負面影響需要時間來治愈。 它也很刺激，會引起強烈的不適。 這些副作用常常使治療變得困難並增加治療費用。 這些因素阻礙了市場的增長。

機會

加強政府支持

國家投入資金研發肝素，療效更高、副作用更小的肝素誕生了。 肝素在減輕疼痛、促進早期康復、減少並發症和縮短住院時間方面非常有效。 因此，政府將缺乏家庭支持與政府資助醫院的免費治療結合起來。 這些方面正在推動市場擴張。

威脅

高昂的醫療費用和嚴格的規定

肝素治療的價格相對較高。 需要每月定期隨訪。 頻繁的治療使其成為最昂貴的藥物。 政府實施嚴格控制，因為高劑量會導致許多副作用。 使用頻率高，副作用多，阻礙了市場拓展。

COVID-19 的影響

COVID-19 疫情大大增加了市場需求。 COVID患者常因促血栓自身抗體產生異常血栓，導致肺栓塞和深靜脈血栓形成，為肝素提供了可乘之機。 低分子肝素早期抗凝治療可有效預防 COVID 相關的凝血功能障礙和內皮損傷，改善患者預後。 這些因素在大流行期間增加了市場需求。

門診部分預計在預測期內最大

門診部分由於其高度便利和服務，預計將有良好的增長。 減少醫院開支，包括與住院和其他招待有關的開支，使門診病人比其他病人更有優勢。 這個市場的很大一部分主要歸功於低價格、擴大的服務範圍和患者的舒適度。

在預測期內，預計靜脈注射業務的複合年增長率最高

由於其可用性，預計靜脈注射部分在預測期內將以最快的複合年增長率增長。 靜脈內給藥是用於給藥肝素，尤其是普通肝素的方法。 它快速進入血液並迅速起作用以避免血栓。 靜脈內給藥還可以更輕鬆地控制血液中的藥物濃度。

市場份額最高的地區

由於心血管疾病和事故的增加，預計在預測期內北美將佔據最大的市場份額。 導致該地區高比例的其他變量包括醫療保健支出的增加和患者對該領域意識的提高。 該地區每年的死亡人數很高，即每 4 人中就有 1 人死亡。 這些因素正在推動該地區對肝素的需求。

複合年增長率最高的地區：

由於老年人口的增加，預計亞太地區在預測期內的複合年增長率最高。 亞太地區也是原料藥和肝素麤品的最大供應商。 這有利於區域性公司，例如 Pharmax Lifesciences。 專利過期藥品的仿製藥在當地廉價生產。 高慢性病人口和不斷擴大的經濟是該地區市場增長的兩個主要驅動力。

主要發展

2022 年 4 月，Novartis宣布引入新的組織結構和運營模式，旨在支持其作為一家專注於未來十年的製藥公司的創新、增長和生產力雄心。.

2022年4月，Dr. Reddy's Laboratories Ltd.（以下簡稱“Dr. Reddy's”及其子公司、MediCane Health Inc.及其子公司宣佈在德國推出醫用大麻產品）宣布：作為一部分根據 Dr.Reddy's 與 MediCane 於 2021 年開始的合作，MediCane 將提供來自葡萄牙 EU-GMP 認證設施的醫用大麻產品，以及後勤和監管支持。/p>

2021 年 3 月，Teva 宣布推出第一個仿製藥 AZOPT(R)（布林佐胺滴眼液）1%。 它用於治療由於高眼壓症和開角型青光眼引起的眼部高血壓。 它通過減少眼球中的液體起作用。 該產品由 Indoco Remedies 開發，將在其位於印度果阿的工廠生產。

我們的報告提供了什麼

  • 區域和國家/地區細分市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場驅動因素（市場趨勢、制約因素、機遇、威脅、挑戰、投資機會、建議等）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局和趨勢
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 供應鏈趨勢反映了最新的技術進步。

提供免費定制

購買此報告的客戶將免費獲得以下定制之一。

  • 公司簡介
    • 其他市場公司的綜合概況（最多 3 家公司）
    • 主要公司的 SWOT 分析（最多 3 家公司）
  • 區域細分
    • 應客戶要求提供主要國家/地區的市場估算、預測和復合年增長率（注意：基於可行性檢查）
  • 競爭基準
    • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究信息來源
    • 二手研究資源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球肝素市場：按來源分類

  • 奶牛
  • 豬
  • 其他來源

第 6 章全球肝素市場：按給藥途徑

  • 皮下
  • 靜脈注射
  • 其他給藥途徑

第 7 章全球肝素市場：按配方分類

  • 解決
  • 注入
  • 其他劑型

第 8 章全球肝素市場：按成分分類

  • 鈉
  • 鈣
  • 其他材料

第 9 章全球肝素市場：按療法分類

  • 呼吸科
  • 心血管
  • 腎臟科
  • 腫瘤學
  • 中樞神經系統
  • 其他治療

第 10 章全球肝素市場：按產品分類

  • 普通肝素
  • 低分子肝素
  • 超低分子量肝素
  • 其他產品

第 11 章全球肝素市場：按應用

  • 深靜脈血栓形成
  • 冠狀動脈疾病
  • 肺栓塞
  • 房顫
  • 靜脈血栓栓塞症
  • 腎功能損害
  • 心髒病發作
  • 其他應用

第 12 章全球肝素市場：按分銷渠道

  • 醫院
  • 藥店
  • 在線藥店
  • 零售藥房

第 13 章全球肝素市場：按最終用戶分類

  • 住院病人
  • 門診
  • 家庭護理
  • 其他最終用戶

第 14 章全球肝素市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東地區

第15章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第十六章公司簡介

  • LEO Pharma A/S
  • Dr. Reddy's Laboratories Ltd
  • Aspen Holdings
  • Novartis AG
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals
  • Fresenius SE & Co
  • Sanofi
  • Viatris Inc
  • Baxter International Inc
  • Pfizer Inc
  • United Biotech Ltd
  • Syntex SA
  • B. Braun Medical Inc
  • Leap Labchem Co
  • Bristol-Myers Squibb Co
  • Anselm Pharmaceuticals
Product Code: SMRC22650

According to Stratistics MRC, the Global Heparin Market is accounted for $7.4 billion in 2022 and is expected to reach $8.6 billion by 2028 growing at a CAGR of 2.4% during the forecast period. Heparin is considered as one of the most essential drug for preserving life. It is a member of the anticoagulant medication family. Heparin is used as therapy for several chronic diseases. The drug possesses potent anti-inflammatory properties. It is injected into a vein or injected under the skin. It manages cardiac, orthopedic, deep vein thrombosis, pulmonary embolism, and renal disorders. Its use also extends to the administration of major orthopedic procedures such as hip and knee replacements. It prevents blood clotting in patients with specific medical conditions or who are undergoing medical procedures such as open-heart surgery, bypass surgery, kidney dialysis, and blood transfusions.

According to CDC in 2022, 659,000 people in the United States die from heart disease each year which is 1 in every 4 deaths and was marked as one of the major causes of death in the country.

Market Dynamics:

Driver:

Growing prevalence of chronic diseases and surgeries

The increasing number of patients having orthopedic, deep vein thrombosis, pulmonary embolism, renal diseases and cardiac operations, as well as the use of heparin in these surgeries raised the usage of heparin. It helps to keep the blood from clotting and prevents excessive coagulation during operations and supports several off-label uses. Heparin mostly helps certain patients, especially those who must have certain types of surgery or who must remain in bed for a long time. These factors are fuelling the market demand.

Restraint:

Adverse side-effects

Heparin misuse or improper dosage can result in joint pain, stiffness, backaches, bleeding, spitting up blood, oozing from wounds and abdominal pain. Negative effects take a while to recover from. They irritate and cause severe discomfort. These side effects frequently make treatment more difficult and raise the total cost of therapy. These factors are hindering the growth of the market.

Opportunity:

Rising government support

Government funds have been raised for heparin research and development that will create it with better therapeutic potential and fewer side effects. Heparin greatly enhances pain relief, promotes quicker recovery, reduces complications, and shortens hospital stays. So, the government combined the lack of familial support with the provision of free care at a government-funded hospital. These aspects are propelling the market expansion.

Threat:

High medical costs & stringent regulations

The price of heparin therapy is relatively high. It requires regular monthly follow ups. Frequent treatments are making it the most costly medication. Government imposed rigorous controls since the heavy dosage of drug causes numerous negative side effects. The market's expansion is being hampered by its increasingly frequent use and negative consequences.

Covid-19 Impact

The COVID-19 epidemic has greatly increased market demand. COVID patients frequently develop aberrant blood clots because of clot-promoting auto antibodies that cause pulmonary embolisms and deep vein thrombosis, which presents a heparin opportunity. Early anticoagulation treatment with low-molecular-weight heparin effectively prevents COVID associated coagulopathy and endotheliopathy, which improve patient prognosis. These factors raised the demand for the market during pandemic.

The outpatient segment is expected to be the largest during the forecast period

The outpatient segment is estimated to have a lucrative growth, due to its high convenience and services. Due to the decrease in hospital expenditures, including those associated with hospital admission and other forms of hospitality, outpatients have an advantage over other patients. The significant proportion of this market is mostly due to low prices, expanded service availability, and patient comfort.

The intravenous segment is expected to have the highest CAGR during the forecast period

The intravenous segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its easy accessibility. The intravenous method is used to give heparin, particularly unfractionated heparin. It allows quick bloodstream entrance and works quickly to avoid blood clots. The intravenous form of administration also makes it simpler to manage drug concentration in the blood.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the increase in cardiovascular diseases and accidents. Other variables that contribute to the region's high proportion include rising healthcare spending and rising patient awareness in this area. This region faces high annual deaths i.e. every 1 in 4 fatalities. These elements are raising the demand for heparin in this region.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the rising geriatric population. Moreover, Asia Pacific is the region that supplies the most API and crude heparin. This benefits regional businesses like Pharmax Lifesciences. Generic versions of medications whose patents have expired are produced locally at a reasonable price. Large chronically ill population and expanding economy are two of the main drivers of the market growth in this region.

Key Players in the market

Some of the key players profiled in the Heparin Market include LEO Pharma A/S, Dr. Reddy's Laboratories Ltd, Aspen Holdings, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceuticals, Fresenius SE & Co, Sanofi, Viatris Inc, Baxter International Inc, Pfizer Inc, United Biotech Ltd, Syntex SA, B. Braun Medical Inc, Leap Labchem Co, Bristol-Myers Squibb Co and Anselm Pharmaceuticals.

Key Developments:

In April 2022, Novartis announced the introduction of a new organizational structure and operating model designed to support the company's innovation, growth, and productivity ambitions as a focused medicines company in the coming decade.

In April 2022, Dr.Reddy's Laboratories Ltd. Along with its subsidiaries together and MediCane Health Inc. with its subsidiaries together announced the launch of its medical cannabis product in Germany. As part of collaboration between Dr. Reddy's and MediCane that started in 2021, MediCane will supply the medical cannabis products to Dr. Reddy's from its EU-GMP-certified facilities in Portugal along with providing logistical and regulatory support.

In March 2021, Teva announced the launch of the first generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%. This is used to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. This works by decreasing the amount of fluid in the eye. The product was developed by Indoco Remedies and will be manufactured at its facility in Goa, India.

Sources Covered:

  • Bovine
  • Porcine
  • Other Sources

Administration Routes Covered:

  • Subcutaneous
  • Intravenous
  • Other Administration Routes

Dosage Forms Covered:

  • Solution
  • Injection
  • Other Dosage Forms

Ingredients Covered:

  • Sodium
  • Calcium
  • Other Ingredients

Therapeutics Covered:

  • Respiratory
  • Cardiovascular
  • Nephrology
  • Oncology
  • Central Nervous System
  • Other Therapeutics

Products Covered:

  • Unfractionated Heparin
  • Low Molecular Weight Heparin
  • Ultra-low Molecular Weight Heparin
  • Other Products

Applications Covered:

  • Deep Vein Thrombosis
  • Coronery Artery Disease
  • Pulmonary Embolism
  • Atrial Fibrillation
  • Venous Thromboembolism
  • Renal Impairment
  • Heart Attack
  • Other Applications

Distribution Channels Covered:

  • Hospitals
  • Drug Stores
  • Online Pharmacies
  • Retail Pharmacies

End Users Covered:

  • Inpatient
  • Outpatient
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Heparin Market, By Source

  • 5.1 Introduction
  • 5.2 Bovine
  • 5.3 Porcine
  • 5.4 Other Sources

6 Global Heparin Market, By Administration Route

  • 6.1 Introduction
  • 6.2 Subcutaneous
  • 6.3 Intravenous
  • 6.4 Other Administration Routes

7 Global Heparin Market, By Dosage Form

  • 7.1 Introduction
  • 7.2 Solution
  • 7.3 Injection
  • 7.4 Other Dosage Forms

8 Global Heparin Market, By Ingredient

  • 8.1 Introduction
  • 8.2 Sodium
  • 8.3 Calcium
  • 8.5 Other Ingredients

9 Global Heparin Market, By Therapeutics

  • 9.1 Introduction
  • 9.2 Respiratory
  • 9.3 Cardiovascular
  • 9.4 Nephrology
  • 9.5 Oncology
  • 9.6 Central Nervous System
  • 9.7 Other Therapeutics

10 Global Heparin Market, By Product

  • 10.1 Introduction
  • 10.2 Unfractionated Heparin
  • 10.3 Low Molecular Weight Heparin
  • 10.4 Ultra-low Molecular Weight Heparin
  • 10.5 Other Products

11 Global Heparin Market, By Application

  • 11.1 Introduction
  • 11.2 Deep Vein Thrombosis
  • 11.3 Coronery Artery Disease
  • 11.4 Pulmonary Embolism
  • 11.5 Atrial Fibrillation
  • 11.6 Venous Thromboembolism
  • 11.7 Renal Impairment
  • 11.8 Heart Attack
  • 11.9 Other Applications

12 Global Heparin Market, By Distribution Channel

  • 12.1 Introduction
  • 12.2 Hospitals
  • 12.3 Drug Stores
  • 12.4 Online Pharmacies
  • 12.5 Retail Pharmacies

13 Global Heparin Market, By End User

  • 13.1 Introduction
  • 13.2 Inpatient
  • 13.3 Outpatient
  • 13.4 Homecare
  • 13.5 Other End Users

14 Global Heparin Market, By Geography

  • 14.1 Introduction
  • 14.2 North America
    • 14.2.1 US
    • 14.2.2 Canada
    • 14.2.3 Mexico
  • 14.3 Europe
    • 14.3.1 Germany
    • 14.3.2 UK
    • 14.3.3 Italy
    • 14.3.4 France
    • 14.3.5 Spain
    • 14.3.6 Rest of Europe
  • 14.4 Asia Pacific
    • 14.4.1 Japan
    • 14.4.2 China
    • 14.4.3 India
    • 14.4.4 Australia
    • 14.4.5 New Zealand
    • 14.4.6 South Korea
    • 14.4.7 Rest of Asia Pacific
  • 14.5 South America
    • 14.5.1 Argentina
    • 14.5.2 Brazil
    • 14.5.3 Chile
    • 14.5.4 Rest of South America
  • 14.6 Middle East & Africa
    • 14.6.1 Saudi Arabia
    • 14.6.2 UAE
    • 14.6.3 Qatar
    • 14.6.4 South Africa
    • 14.6.5 Rest of Middle East & Africa

15 Key Developments

  • 15.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 15.2 Acquisitions & Mergers
  • 15.3 New Product Launch
  • 15.4 Expansions
  • 15.5 Other Key Strategies

16 Company Profiling

  • 16.1 LEO Pharma A/S
  • 16.2 Dr. Reddy's Laboratories Ltd
  • 16.3 Aspen Holdings
  • 16.4 Novartis AG
  • 16.5 GlaxoSmithKline plc
  • 16.6 Teva Pharmaceuticals
  • 16.7 Fresenius SE & Co
  • 16.8 Sanofi
  • 16.9 Viatris Inc
  • 16.10 Baxter International Inc
  • 16.11 Pfizer Inc
  • 16.12 United Biotech Ltd
  • 16.13 Syntex SA
  • 16.14 B. Braun Medical Inc
  • 16.15 Leap Labchem Co
  • 16.16 Bristol-Myers Squibb Co
  • 16.17 Anselm Pharmaceuticals

List of Tables

  • Table 1 Global Heparin Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Heparin Market Outlook, By Source (2020-2028) ($MN)
  • Table 3 Global Heparin Market Outlook, By Bovine (2020-2028) ($MN)
  • Table 4 Global Heparin Market Outlook, By Porcine (2020-2028) ($MN)
  • Table 5 Global Heparin Market Outlook, By Other Sources (2020-2028) ($MN)
  • Table 6 Global Heparin Market Outlook, By Administration Route (2020-2028) ($MN)
  • Table 7 Global Heparin Market Outlook, By Subcutaneous (2020-2028) ($MN)
  • Table 8 Global Heparin Market Outlook, By Intravenous (2020-2028) ($MN)
  • Table 9 Global Heparin Market Outlook, By Other Administration Routes (2020-2028) ($MN)
  • Table 10 Global Heparin Market Outlook, By Dosage Form (2020-2028) ($MN)
  • Table 11 Global Heparin Market Outlook, By Solution (2020-2028) ($MN)
  • Table 12 Global Heparin Market Outlook, By Injection (2020-2028) ($MN)
  • Table 13 Global Heparin Market Outlook, By Other Dosage Forms (2020-2028) ($MN)
  • Table 14 Global Heparin Market Outlook, By Ingredient (2020-2028) ($MN)
  • Table 15 Global Heparin Market Outlook, By Sodium (2020-2028) ($MN)
  • Table 16 Global Heparin Market Outlook, By Calcium (2020-2028) ($MN)
  • Table 17 Global Heparin Market Outlook, By Other Ingredients (2020-2028) ($MN)
  • Table 18 Global Heparin Market Outlook, By Therapeutics (2020-2028) ($MN)
  • Table 19 Global Heparin Market Outlook, By Respiratory (2020-2028) ($MN)
  • Table 20 Global Heparin Market Outlook, By Cardiovascular (2020-2028) ($MN)
  • Table 21 Global Heparin Market Outlook, By Nephrology (2020-2028) ($MN)
  • Table 22 Global Heparin Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 23 Global Heparin Market Outlook, By Central Nervous System (2020-2028) ($MN)
  • Table 24 Global Heparin Market Outlook, By Other Therapeutics (2020-2028) ($MN)
  • Table 25 Global Heparin Market Outlook, By Product (2020-2028) ($MN)
  • Table 26 Global Heparin Market Outlook, By Unfractionated Heparin (2020-2028) ($MN)
  • Table 27 Global Heparin Market Outlook, By Low Molecular Weight Heparin (2020-2028) ($MN)
  • Table 28 Global Heparin Market Outlook, By Ultra-low Molecular Weight Heparin (2020-2028) ($MN)
  • Table 29 Global Heparin Market Outlook, By Other Products (2020-2028) ($MN)
  • Table 30 Global Heparin Market Outlook, By Application (2020-2028) ($MN)
  • Table 31 Global Heparin Market Outlook, By Deep Vein Thrombosis (2020-2028) ($MN)
  • Table 32 Global Heparin Market Outlook, By Coronery Artery Disease (2020-2028) ($MN)
  • Table 33 Global Heparin Market Outlook, By Pulmonary Embolism (2020-2028) ($MN)
  • Table 34 Global Heparin Market Outlook, By Atrial Fibrillation (2020-2028) ($MN)
  • Table 35 Global Heparin Market Outlook, By Venous Thromboembolism (2020-2028) ($MN)
  • Table 36 Global Heparin Market Outlook, By Renal Impairment (2020-2028) ($MN)
  • Table 37 Global Heparin Market Outlook, By Heart Attack (2020-2028) ($MN)
  • Table 38 Global Heparin Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 39 Global Heparin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 40 Global Heparin Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 41 Global Heparin Market Outlook, By Drug Stores (2020-2028) ($MN)
  • Table 42 Global Heparin Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 43 Global Heparin Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 44 Global Heparin Market Outlook, By End User (2020-2028) ($MN)
  • Table 45 Global Heparin Market Outlook, By Inpatient (2020-2028) ($MN)
  • Table 46 Global Heparin Market Outlook, By Outpatient (2020-2028) ($MN)
  • Table 47 Global Heparin Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 48 Global Heparin Market Outlook, By Other End Users (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.